Tumors With Aberrations in ALK
1 clinical trials · Condition
◉ Watch Tumors With Aberrations in ALK
| Record | Firm | Date |
|---|---|---|
| Ceritinib Rare Indications Study in ALK+ Tumors (NCT02465528) | Novartis Pharmaceuticals | 2016-05-06 |
Track Tumors With Aberrations in ALK automatically
Every clearance here is in the API, with alerts when new ones post.